[Candida infection of the skin and mucous membranes still a topic. Administering azoles with clinical understanding].
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D017964:Itraconazole / Q000009:adverse effects / Q000627:therapeutic use*; D007654:Ketoconazole / Q000009:adverse effects / Q000627:therapeutic use*
D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole